<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38459022</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis.</ArticleTitle><Pagination><StartPage>2133</StartPage><MedlinePgn>2133</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2133</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-46560-w</ELocationID><Abstract><AbstractText>Many countries continue to experience pertussis epidemics despite widespread vaccination. Waning protection after booster vaccination has highlighted the need for a better understanding of the immunological factors that promote durable protection. Here we apply systems vaccinology to investigate antibody responses in adolescents in the Netherlands (N = 14; NL) and the United Kingdom (N = 12; UK) receiving a tetanus-diphtheria-acellular pertussis-inactivated poliovirus (Tdap-IPV) vaccine. We report that early antiviral and interferon gene expression signatures in blood correlate to persistence of pertussis-specific antibody responses. Single-cell analyses of the innate response identified monocytes and myeloid dendritic cells (MoDC) as principal responders that upregulate antiviral gene expression and type-I interferon cytokine production. With public data, we show that Tdap vaccination stimulates significantly lower antiviral/type-I interferon responses than Tdap-IPV, suggesting that IPV may promote antiviral gene expression. Subsequent in vitro stimulation experiments demonstrate TLR-dependent, IPV-specific activation of the pro-inflammatory p38 MAP kinase pathway in MoDCs. Together, our data provide insights into the molecular host response to pertussis booster vaccination and demonstrate that IPV enhances innate immune activity associated with persistent, pertussis-specific antibody responses.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gillard</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suffiotti</LastName><ForeName>Madeleine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brazda</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0215-1692</Identifier><AffiliationInfo><Affiliation>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatasubramanian</LastName><ForeName>Prashanna B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Versteegen</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9946-0933</Identifier><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jonge</LastName><ForeName>Marien I</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0003-2812-5895</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bibi</LastName><ForeName>Sagida</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Marta Valente</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health &amp; Science, Caparica, Almada, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonetti</LastName><ForeName>Elles</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babiceanu</LastName><ForeName>Mihaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sanofi Pasteur VaxDesign, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettring</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sanofi Pasteur VaxDesign, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teodosio</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2097-7199</Identifier><AffiliationInfo><Affiliation>Leiden University Medical Center, Immunohematology &amp; Blood Transfusion, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Groot</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berbers</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stunnenberg</LastName><ForeName>Hendrik G</ForeName><Initials>HG</Initials><Identifier Source="ORCID">0000-0002-0066-1576</Identifier><AffiliationInfo><Affiliation>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schanen</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sanofi Pasteur VaxDesign, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fenwick</LastName><ForeName>Craig</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9435-0110</Identifier><AffiliationInfo><Affiliation>Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huynen</LastName><ForeName>Martijn A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-6189-5491</Identifier><AffiliationInfo><Affiliation>Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Diavatopoulos</LastName><ForeName>Dimitri A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-7065-7807</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. dimitri.diavatopoulos@radboudumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. dimitri.diavatopoulos@radboudumc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022681">Diphtheria-Tetanus-acellular Pertussis Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001886" MajorTopicYN="N">Bordetella pertussis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013742" MajorTopicYN="Y">Tetanus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014917" MajorTopicYN="Y">Whooping Cough</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004165" MajorTopicYN="Y">Diphtheria</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022681" MajorTopicYN="Y">Diphtheria-Tetanus-acellular Pertussis Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003352" MajorTopicYN="N">Corynebacterium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>C.T. reports inventorship of the patent “Means and methods for multiparameter cytometry-based leukocyte subsetting” (NL2844751, filing date 5 November 2019), owned by the EuroFlow Consortium. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>9</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38459022</ArticleId><ArticleId IdType="pmc">PMC10923912</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-46560-w</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-46560-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hegerle N, Guiso N. Epidemiology of whooping cough &amp; typing of Bordetella pertussis. Future Microbiol. 2013;8:1391–1403. doi: 10.2217/fmb.13.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.13.111</ArticleId><ArticleId IdType="pubmed">24199799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson DW, Rohani P. Perplexities of pertussis: recent global epidemiological trends and their potential causes. Epidemiol. Infect. 2014;142:672–684. doi: 10.1017/S0950268812003093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268812003093</ArticleId><ArticleId IdType="pmc">PMC9151176</ArticleId><ArticleId IdType="pubmed">23324361</ArticleId></ArticleIdList></Reference><Reference><Citation>European centre for disease prevention and control, Vaccine schedules in all countries in the EU/EEA. https://vaccine-schedule.ecdc.europa.eu (2021).</Citation></Reference><Reference><Citation>Grimprel E, et al. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine. 2005;23:3657–3667. doi: 10.1016/j.vaccine.2005.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.02.013</ArticleId><ArticleId IdType="pubmed">15882526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert EE, et al. Uncovering distinct primary vaccination-dependent profiles in human bordetella pertussis specific CD4+ T-Cell responses using a novel whole blood assay. Vaccines. 2020;8:225. doi: 10.3390/vaccines8020225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8020225</ArticleId><ArticleId IdType="pmc">PMC7349943</ArticleId><ArticleId IdType="pubmed">32429152</ArticleId></ArticleIdList></Reference><Reference><Citation>Versteegen P, et al. Memory B cell activation induced by pertussis booster vaccination in four age groups of three countries. Front. Immunol. 2022;13:864674. doi: 10.3389/fimmu.2022.864674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.864674</ArticleId><ArticleId IdType="pmc">PMC9168128</ArticleId><ArticleId IdType="pubmed">35677044</ArticleId></ArticleIdList></Reference><Reference><Citation>Versteegen P, et al. Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: a collaborative study in Finland, the Netherlands, and the United Kingdom. EBioMedicine. 2021;65:103247. doi: 10.1016/j.ebiom.2021.103247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103247</ArticleId><ArticleId IdType="pmc">PMC7920834</ArticleId><ArticleId IdType="pubmed">33647770</ArticleId></ArticleIdList></Reference><Reference><Citation>Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907–1916. doi: 10.1016/S0264-410X(98)00227-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(98)00227-8</ArticleId><ArticleId IdType="pubmed">9796042</ArticleId></ArticleIdList></Reference><Reference><Citation>Taranger J, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J. Infect. Dis. 2000;181:1010–1013. doi: 10.1086/315318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315318</ArticleId><ArticleId IdType="pubmed">10720524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16:1901–1906. doi: 10.1016/S0264-410X(98)00226-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(98)00226-6</ArticleId><ArticleId IdType="pubmed">9796041</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N. Engl. J. Med. 2012;367:1012–1019. doi: 10.1056/NEJMoa1200850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1200850</ArticleId><ArticleId IdType="pubmed">22970945</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano M, et al. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr. 1998;132:983–988. doi: 10.1016/S0022-3476(98)70395-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(98)70395-6</ArticleId><ArticleId IdType="pubmed">9627590</ArticleId></ArticleIdList></Reference><Reference><Citation>von Konig CHW. Acellular pertussis vaccines: where to go to? Lancet Infect. Dis. 2018;18:5–6. doi: 10.1016/S1473-3099(17)30613-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30613-8</ArticleId><ArticleId IdType="pubmed">29066129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124:849–863. doi: 10.1016/j.cell.2006.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.02.019</ArticleId><ArticleId IdType="pubmed">16497593</ArticleId></ArticleIdList></Reference><Reference><Citation>Querec TD, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2009;10:116–125. doi: 10.1038/ni.1688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1688</ArticleId><ArticleId IdType="pmc">PMC4049462</ArticleId><ArticleId IdType="pubmed">19029902</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves E, et al. Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination. J. Clin. Invest. 2019;129:1960–1971. doi: 10.1172/JCI125372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI125372</ArticleId><ArticleId IdType="pmc">PMC6486343</ArticleId><ArticleId IdType="pubmed">30843873</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 2014;15:195–204. doi: 10.1038/ni.2789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2789</ArticleId><ArticleId IdType="pmc">PMC3946932</ArticleId><ArticleId IdType="pubmed">24336226</ArticleId></ArticleIdList></Reference><Reference><Citation>Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl Acad. Sci. USA. 2014;111:787–792. doi: 10.1073/pnas.1314688110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1314688110</ArticleId><ArticleId IdType="pmc">PMC3896208</ArticleId><ArticleId IdType="pubmed">24277828</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya HI, et al. Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity. 2015;43:1186–1198. doi: 10.1016/j.immuni.2015.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.11.012</ArticleId><ArticleId IdType="pmc">PMC4859820</ArticleId><ArticleId IdType="pubmed">26682988</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya HI, et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 2011;12:786–795. doi: 10.1038/ni.2067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2067</ArticleId><ArticleId IdType="pmc">PMC3140559</ArticleId><ArticleId IdType="pubmed">21743478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtien A, et al. Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV. Cell Rep. 2017;20:2251–2261. doi: 10.1016/j.celrep.2017.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.023</ArticleId><ArticleId IdType="pmc">PMC5583508</ArticleId><ArticleId IdType="pubmed">28854372</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermoser G, et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity. 2013;38:831–844. doi: 10.1016/j.immuni.2012.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.12.008</ArticleId><ArticleId IdType="pmc">PMC3681204</ArticleId><ArticleId IdType="pubmed">23601689</ArticleId></ArticleIdList></Reference><Reference><Citation>Macina, D. &amp; Evans, K. E. Bordetella pertussis in school-age children, adolescents and adults: a systematic review of epidemiology and mortality in Europe. Infect. Dis. Ther.4, 2071–2118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387212</ArticleId><ArticleId IdType="pubmed">34435338</ArticleId></ArticleIdList></Reference><Reference><Citation>Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in Asia. Infect. Dis. Ther. 2021;10:1115–1140. doi: 10.1007/s40121-021-00439-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00439-1</ArticleId><ArticleId IdType="pmc">PMC8322225</ArticleId><ArticleId IdType="pubmed">33928533</ArticleId></ArticleIdList></Reference><Reference><Citation>Domenech de Celles M, Magpantay FMG, King AA, Rohani P. The impact of past vaccination coverage and immunity on pertussis resurgence. Sci. Transl. Med. 2018;10:eaaj1748. doi: 10.1126/scitranslmed.aaj1748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaj1748</ArticleId><ArticleId IdType="pmc">PMC6063734</ArticleId><ArticleId IdType="pubmed">29593103</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Antunes R, et al. A system-view of Bordetella pertussis booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy. JCI Insight. 2021;6:e141023. doi: 10.1172/jci.insight.141023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.141023</ArticleId><ArticleId IdType="pmc">PMC8119213</ArticleId><ArticleId IdType="pubmed">33690224</ArticleId></ArticleIdList></Reference><Reference><Citation>Blok BA, et al. Interacting, nonspecific, immunological effects of bacille calmette-guerin and tetanus-diphtheria-pertussis inactivated polio vaccinations: an explorative, randomized trial. Clin. Infect. Dis. 2020;70:455–463.</Citation><ArticleIdList><ArticleId IdType="pubmed">30919883</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepp RM, Berbers GA, Ferreira JA, Reimerink JH, van der Klis FR. A novel multiplex poliovirus binding inhibition assay applicable for large serosurveillance and vaccine studies, without the use of live poliovirus. J. Virol. Methods. 2017;241:15–23. doi: 10.1016/j.jviromet.2016.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2016.12.006</ArticleId><ArticleId IdType="pubmed">27988324</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J. Immunol. Methods. 2008;335:79–89. doi: 10.1016/j.jim.2008.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2008.02.018</ArticleId><ArticleId IdType="pubmed">18407287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongen E, et al. Sex differences in the blood transcriptome identify robust changes in immune cell proportions with aging and influenza infection. Cell Rep. 2019;29:1961–1973 e1964. doi: 10.1016/j.celrep.2019.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.10.019</ArticleId><ArticleId IdType="pmc">PMC6856718</ArticleId><ArticleId IdType="pubmed">31722210</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang JS, et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell. 2014;157:499–513. doi: 10.1016/j.cell.2014.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.03.031</ArticleId><ArticleId IdType="pmc">PMC4139290</ArticleId><ArticleId IdType="pubmed">24725414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucasas KL, et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J. Infect. Dis. 2011;203:921–929. doi: 10.1093/infdis/jiq156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiq156</ArticleId><ArticleId IdType="pmc">PMC3068032</ArticleId><ArticleId IdType="pubmed">21357945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000;25:25–29. doi: 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuznik A, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 2011;186:4794–4804. doi: 10.4049/jimmunol.1000702.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000702</ArticleId><ArticleId IdType="pubmed">21398612</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. The complete routine immunisation schedule from February 2022. https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule/the-complete-routine-immunisation-schedule-from-february-2022 (2022).</Citation></Reference><Reference><Citation>Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev. Vaccines. 2008;7:97–115. doi: 10.1586/14760584.7.1.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.7.1.97</ArticleId><ArticleId IdType="pubmed">18251697</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard M, Law JC, Edilova MI, Watts TH. Type I interferons drive the maturation of human DC3s with a distinct costimulatory profile characterized by high GITRL. Sci. Immunol. 2020;5:eabe0347. doi: 10.1126/sciimmunol.abe0347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe0347</ArticleId><ArticleId IdType="pubmed">33188059</ArticleId></ArticleIdList></Reference><Reference><Citation>Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8:363–372. doi: 10.1016/S1074-7613(00)80541-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80541-5</ArticleId><ArticleId IdType="pubmed">9529153</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bon A, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14:461–470. doi: 10.1016/S1074-7613(01)00126-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(01)00126-1</ArticleId><ArticleId IdType="pubmed">11336691</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson CL, et al. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J. Exp. Med. 2010;207:1485–1500. doi: 10.1084/jem.20092695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20092695</ArticleId><ArticleId IdType="pmc">PMC2901065</ArticleId><ArticleId IdType="pubmed">20566717</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bon A, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 2006;176:2074–2078. doi: 10.4049/jimmunol.176.4.2074.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.4.2074</ArticleId><ArticleId IdType="pubmed">16455962</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 2012;5:485–500. doi: 10.1038/mi.2012.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2012.54</ArticleId><ArticleId IdType="pubmed">22718262</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lee S, et al. Robust humoral and cellular immune responses to pertussis in adults after a first acellular booster vaccination. Front Immunol. 2018;9:681. doi: 10.3389/fimmu.2018.00681.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00681</ArticleId><ArticleId IdType="pmc">PMC5893963</ArticleId><ArticleId IdType="pubmed">29670634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton T, Dunn G, Eastwood D, Minor PD, Martin J. Effect of formaldehyde inactivation on poliovirus. J. Virol. 2014;88:11955–11964. doi: 10.1128/JVI.01809-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01809-14</ArticleId><ArticleId IdType="pmc">PMC4178759</ArticleId><ArticleId IdType="pubmed">25100844</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsbach A, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 2008;180:3729–3738. doi: 10.4049/jimmunol.180.6.3729.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.6.3729</ArticleId><ArticleId IdType="pubmed">18322178</ArticleId></ArticleIdList></Reference><Reference><Citation>Georg P, Sander LE. Innate sensors that regulate vaccine responses. Curr. Opin. Immunol. 2019;59:31–41. doi: 10.1016/j.coi.2019.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2019.02.006</ArticleId><ArticleId IdType="pubmed">30978666</ArticleId></ArticleIdList></Reference><Reference><Citation>National Library of Medicine. Genome information by organism: Enterovirus C. https://www.ncbi.nlm.nih.gov/genome/browse/#!/viruses/10305/ (2023).</Citation></Reference><Reference><Citation>Varney ME, et al. Bordetella pertussis whole cell immunization, unlike acellular immunization, mimics naive infection by driving hematopoietic stem and progenitor cell expansion in mice. Front. Immunol. 2018;9:2376. doi: 10.3389/fimmu.2018.02376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02376</ArticleId><ArticleId IdType="pmc">PMC6200895</ArticleId><ArticleId IdType="pubmed">30405604</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois V, et al. Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage. NPJ Vaccines. 2021;6:6. doi: 10.1038/s41541-020-00270-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-00270-8</ArticleId><ArticleId IdType="pmc">PMC7794405</ArticleId><ArticleId IdType="pubmed">33420041</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiducci C, et al. RNA recognition by human TLR8 can lead to autoimmune inflammation. J. Exp. Med. 2013;210:2903–2919. doi: 10.1084/jem.20131044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20131044</ArticleId><ArticleId IdType="pmc">PMC3865472</ArticleId><ArticleId IdType="pubmed">24277153</ArticleId></ArticleIdList></Reference><Reference><Citation>Misiak A, et al. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. Vaccine. 2017;35:5256–5263. doi: 10.1016/j.vaccine.2017.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.08.009</ArticleId><ArticleId IdType="pubmed">28823618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasturi SP, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470:543–547. doi: 10.1038/nature09737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09737</ArticleId><ArticleId IdType="pmc">PMC3057367</ArticleId><ArticleId IdType="pubmed">21350488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasturi SP, et al. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci. Immunol. 2020;5:eabb1025. doi: 10.1126/sciimmunol.abb1025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abb1025</ArticleId><ArticleId IdType="pmc">PMC8109745</ArticleId><ArticleId IdType="pubmed">32561559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. Curr. Opin. Immunol. 2019;59:72–78. doi: 10.1016/j.coi.2019.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2019.03.006</ArticleId><ArticleId IdType="pmc">PMC6774807</ArticleId><ArticleId IdType="pubmed">31078081</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe J, et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect. Immun. 2005;73:8130–8135. doi: 10.1128/IAI.73.12.8130-8135.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.73.12.8130-8135.2005</ArticleId><ArticleId IdType="pmc">PMC1307058</ArticleId><ArticleId IdType="pubmed">16299307</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanger R, et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur. J. Pediatr. 2007;166:1229–1236. doi: 10.1007/s00431-006-0403-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-006-0403-x</ArticleId><ArticleId IdType="pubmed">17235521</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergara R, et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur. J. Pediatr. 2005;164:377–382. doi: 10.1007/s00431-005-1650-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-005-1650-y</ArticleId><ArticleId IdType="pubmed">15782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Knuf M, et al. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix IPV) Hum. Vaccin. 2010;6:554–561. doi: 10.4161/hv.6.7.11760.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.6.7.11760</ArticleId><ArticleId IdType="pubmed">20448468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbo O, et al. Acellular pertussis vaccine effectiveness over time. Pediatrics. 2019;144:e20183466. doi: 10.1542/peds.2018-3466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2018-3466</ArticleId><ArticleId IdType="pmc">PMC6615519</ArticleId><ArticleId IdType="pubmed">31182549</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver SE, Moore KL. Licensure of a diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine, and guidance for use in infants. MMWR Morb. Mortal. Wkly Rep. 2020;69:136–139. doi: 10.15585/mmwr.mm6905a5.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6905a5</ArticleId><ArticleId IdType="pmc">PMC7004397</ArticleId><ArticleId IdType="pubmed">32027629</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England. Hexavalent combination vaccine: programme guidance. https://www.gov.uk/government/publications/hexavalent-combination-vaccine-programme-guidance (2017).</Citation></Reference><Reference><Citation>Winter K, Klein NP, Ackley S, Cherry JD. Comment on “The impact of past vaccination coverage and immunity on pertussis resurgence”. Sci. Transl. Med. 2018;10:eaau0548. doi: 10.1126/scitranslmed.aau0548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau0548</ArticleId><ArticleId IdType="pubmed">30567926</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. Vaccines Licensed for Use in the United States. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states (2023).</Citation></Reference><Reference><Citation>Hampton LM, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. MMWR Morb. Mortal. Wkly Rep. 2016;65:934–938. doi: 10.15585/mmwr.mm6535a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6535a3</ArticleId><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect. Dis. 2021;21:559–568. doi: 10.1016/S1473-3099(20)30555-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30555-7</ArticleId><ArticleId IdType="pmc">PMC7992032</ArticleId><ArticleId IdType="pubmed">33284114</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowicka M, et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Res. 2017;6:748. doi: 10.12688/f1000research.11622.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.11622.1</ArticleId><ArticleId IdType="pmc">PMC5473464</ArticleId><ArticleId IdType="pubmed">28663787</ArticleId></ArticleIdList></Reference><Reference><Citation>Argelaguet R, et al. MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data. Genome Biol. 2020;21:111. doi: 10.1186/s13059-020-02015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-020-02015-1</ArticleId><ArticleId IdType="pmc">PMC7212577</ArticleId><ArticleId IdType="pubmed">32393329</ArticleId></ArticleIdList></Reference><Reference><Citation>Günther, P. C. et al. A rule-based data-informed cellular consensus map of the human mononuclear phagocyte cell space. bioRxiv, (2019).</Citation></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D, Machler M, Bolker BM, Walker SC. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 2015;67:1–48. doi: 10.18637/jss.v067.i01.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J. Stat. Softw. 2017;82:1–26. doi: 10.18637/jss.v082.i13.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v082.i13</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate—a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 1995;57:289–300.</Citation></Reference><Reference><Citation>Gillard, J. Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to pertussis. 10.5281/zenodo.10560736 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38459022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>